Eupraxia Reports Q2 2026 Results: $133.6M Cash, Runway into 2H 2028, Phase 2b EoE Data Expected Q4
EPRX sits 33% above its 52-week low of $5.04.
Summary
Eupraxia Pharmaceuticals reported Q2 2026 results with $133.6 million in cash and short-term investments, extending its runway into the second half of 2028. The company is advancing its lead program EP-104GI for eosinophilic esophagitis, with interim Phase 2b data expected in Q4 2026.
Key Events · Earnings and Guidance · EPRX
-
Strong Cash Position
Cash and equivalents of $52.4M plus short-term investments of $81.2M total $133.6M, funding operations into the second half of 2028.
-
Q2 Net Loss Widens
Net loss of $14.5M vs. $8.7M in Q2 2025, driven by a doubling of R&D expenses to $12.8M as the RESOLVE trial expands.
-
Phase 2b Data Catalyst
Interim data from the randomized, placebo-controlled Phase 2b portion of the RESOLVE trial in EoE expected in Q4 2026.
-
Executive Team Strengthened
Appointed Dr. Jeymi Tambiah as CMO, Dr. Jeff Millard as EVP Technical Operations, and added three industry leaders to the Board.
Analysis · EPRX · Life Sciences
A robust cash position of $133.6 million funds Eupraxia's operations into the second half of 2028, even as the net loss widened to $14.5 million on a doubling of R&D spend to advance the RESOLVE trial. The key catalyst ahead is interim Phase 2b data for EP-104GI in eosinophilic esophagitis, expected in Q4 2026. Recent executive hires and a restructuring to Vancouver/Seattle hubs signal preparation for late-stage development and potential commercialization.
At the time of this filing, EPRX was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $437.7M. The 52-week trading range was $5.04 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.